Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology ++ +...

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-8KGpoy87VI4ht9FYkINihi8PvuSRwkHWCVB3G75Ms9LnxUXLu7fG0wtuA1WLiBXtkOnWj4rImaLvzaCaNVLgE7NWsZ8Q&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00295-9/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--uO0YWGE69YvRfurJq8h-auWMBUoABX5SKuwQOWl8klgI_CeP54dTefS36F5f1aY3yQkpMkagDkis00W9HgNjRSDAvkA&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol12no12/PIIS2352-3026(25)X0012-0